Publications Archive - Scholar Rock https://scholarrock.com/publications/ Mon, 22 Jul 2024 14:31:28 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.1 https://scholarrock.com/wp-content/uploads/2020/08/cropped-favicon-32x32.png Publications Archive - Scholar Rock https://scholarrock.com/publications/ 32 32 Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study https://scholarrock.com/publications/long-term-efficacy-safety-and-patient-reported-outcomes-of-apitegromab-in-patients-with-spinal-muscular-atrophy-results-from-the-36-month-topaz-study/ Mon, 22 Jul 2024 14:31:27 +0000 https://scholarrock.com/?post_type=publication&p=1188 The post Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study appeared first on Scholar Rock.

]]> The post Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study appeared first on Scholar Rock.

]]> An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis https://scholarrock.com/publications/an-antibody-that-inhibits-tgf-%ce%b21-release-from-latent-extracellular-matrix-complexes-attenuates-the-progression-of-renal-fibrosis/ Tue, 09 Jul 2024 13:27:32 +0000 https://scholarrock.com/?post_type=publication&p=1187 The post An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis appeared first on Scholar Rock.

]]> The post An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis appeared first on Scholar Rock.

]]> Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3 https://scholarrock.com/publications/safety-and-efficacy-of-apitegromab-in-patients-with-spinal-muscular-atrophy-types-2-and-3/ Fri, 09 Feb 2024 22:21:17 +0000 https://scholarrock.com/?post_type=publication&p=1161 The post Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3 appeared first on Scholar Rock.

]]> The post Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3 appeared first on Scholar Rock.

]]> Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease https://scholarrock.com/publications/preclinical-safety-assessment-and-toxicokinetics-of-apitegromab-an-antibody-targeting-proforms-of-myostatin-for-the-treatment-of-muscle-atrophying-disease/ Wed, 14 Jul 2021 17:54:25 +0000 https://scholarrock.com/?post_type=publication&p=1005 The post Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease appeared first on Scholar Rock.

]]> The post Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease appeared first on Scholar Rock.

]]> A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy https://scholarrock.com/publications/a-randomized-phase-1-safety-pharmacokinetic-and-pharmacodynamic-study-of-the-novel-myostatin-inhibitor-apitegromab-srk-015-a-potential-treatment-for-spinal-muscular-atrophy/ Tue, 11 May 2021 19:20:48 +0000 https://scholarrock.com/?post_type=publication&p=989 The post A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy appeared first on Scholar Rock.

]]> The post A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy appeared first on Scholar Rock.

]]> Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors https://scholarrock.com/publications/nonclinical-development-of-srk-181-an-anti-latent-tgf%ce%b21-monoclonal-antibody-for-the-treatment-of-locally-advanced-or-metastatic-solid-tumors/ Mon, 22 Mar 2021 20:17:38 +0000 https://scholarrock.com/?post_type=publication&p=976 The post Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors appeared first on Scholar Rock.

]]> The post Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors appeared first on Scholar Rock.

]]> Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015 https://scholarrock.com/publications/structural-basis-of-specific-inhibition-of-extracellular-activation-of-pro-or-latent-myostatin-by-the-monoclonal-antibody-srk-015/ Fri, 17 Apr 2020 15:24:07 +0000 https://scholarrock301.wpengine.com/?post_type=publication&p=666 The post Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015 appeared first on Scholar Rock.

]]> The post Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015 appeared first on Scholar Rock.

]]> Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape https://scholarrock.com/publications/selective-inhibition-of-tgfb1-activation-overcomes-primary-resistance-to-checkpoint-blockade-therapy-by-altering-tumor-immune-landscape/ Wed, 25 Mar 2020 15:24:58 +0000 https://scholarrock301.wpengine.com/?post_type=publication&p=667 The post Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape appeared first on Scholar Rock.

]]> The post Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape appeared first on Scholar Rock.

]]> A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation https://scholarrock.com/publications/a-sensitive-and-selective-immunoassay-for-the-quantitation-of-serum-latent-myostatin-after-in-vivo-administration-of-srk-015-a-selective-inhibitor-of-myostatin-activation/ Fri, 26 Jul 2019 15:25:34 +0000 https://scholarrock301.wpengine.com/?post_type=publication&p=668 The post A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation appeared first on Scholar Rock.

]]> The post A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation appeared first on Scholar Rock.

]]> Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy https://scholarrock.com/publications/specific-inhibition-of-myostatin-activation-is-beneficial-in-mouse-models-of-sma-therapy/ Mon, 01 Apr 2019 15:30:43 +0000 https://scholarrock301.wpengine.com/?post_type=publication&p=669 The post Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy appeared first on Scholar Rock.

]]> The post Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy appeared first on Scholar Rock.

]]>